{"id":864902,"date":"2026-05-15T08:31:33","date_gmt":"2026-05-15T06:31:33","guid":{"rendered":"https:\/\/intervacc.se\/?p=864902"},"modified":"2026-05-15T08:31:34","modified_gmt":"2026-05-15T06:31:34","slug":"emil-billback-appointed-new-chair-of-the-board-of-intervacc","status":"publish","type":"post","link":"https:\/\/intervacc.se\/en\/emil-billback-appointed-new-chair-of-the-board-of-intervacc\/","title":{"rendered":"Emil Billb\u00e4ck appointed new Chair of the Board of Intervacc"},"content":{"rendered":"
\n

Intervacc AB (publ), a growth company within veterinary medicine with its vaccine Strangvac\u00ae<\/sup> registered in 16 European countries, today announces that Chairman of the Board H\u00e5kan Bj\u00f6rklund has handed over to Emil Billb\u00e4ck, previously a Board member, who was elected as the new Chair at the Annual General Meeting held on Wednesday. Continuity is ensured as H\u00e5kan Bj\u00f6rklund remains on the Board as a non-executive Director.<\/p>\n<\/div>\n\n\n

The appointment represents a natural step in the Company\u2019s development, with a primary focus on growth and scaling. Intervacc\u2019s new Chair, Emil Billb\u00e4ck, brings extensive experience in market entry for smaller biotech companies at the early stages of their growth journey, which is highly relevant to Intervacc\u2019s current phase of development.<\/p>\n\n\n\n

\u201cIt is an honour to lead the Board of Intervacc. We are entering an exciting phase where the equine vaccine Strangvac\u00ae<\/sup> is to be approved and launched in the United States, followed by advancing the porcine vaccine Piggivac\u2122 towards market authorization. My focus will be, together with the Board and management, to realize the full potential of our technology portfolio,\u201d<\/em> says Emil Billb\u00e4ck.<\/p>\n\n\n\n

The right time for a transition<\/h2>\n\n\n\n

H\u00e5kan Bj\u00f6rklund, who has served as Chair of Intervacc until now, believes the timing is right to pass the gavel to Emil Billb\u00e4ck.<\/p>\n\n\n\n

\u201cIntervacc is now accelerating, and Emil\u2019s expertise in sales and marketing complements the CEO, Carl-Johan Dalsgaard\u2019s, strong background in science and pharmaceutical development. A further significant advantage is that they have previously successfully navigated companies through critical commercial and financial transitions,\u201d<\/em> says H\u00e5kan Bj\u00f6rklund, who will continue to serve on the Board.<\/p>\n\n\n\n

For more information please contact:<\/strong>
Carl-Johan Dalsgaard, CEO
Phone: +46 (0)8 120 10 600
E-mail: carl-johan.dalsgaard@intervacc.se<\/p>\n\n\n\n

The information was submitted for publication, through the agency of the contact person set out above on May 15, 2026 at 08.30 CET.<\/em><\/p>\n\n\n\n

About Intervacc<\/strong>
Intervacc AB is an animal health group that develops vaccines for animals. The company\u2019s vaccines and vaccine candidates are based on many years of research at the Karolinska Institute and the Swedish University of Agricultural Sciences. The Intervacc share (Nasdaq: IVACC) is listed on the Nasdaq First North Growth Market. For more information, see intervacc.se<\/p>\n\n\n\n

Contact information for Certified Adviser<\/strong>
Eminova Fondkommission AB
E-mail: adviser@eminova.se, Phone: +46 (0)8 \u2013 684 211 10<\/p>\n","protected":false},"excerpt":{"rendered":"

Intervacc AB (publ), a growth company within veterinary medicine with its vaccine Strangvac\u00ae registered in 16 European countries, today announces […]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false},"categories":[27],"tags":[],"_links":{"self":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/864902"}],"collection":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/comments?post=864902"}],"version-history":[{"count":11,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/864902\/revisions"}],"predecessor-version":[{"id":865052,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/posts\/864902\/revisions\/865052"}],"wp:attachment":[{"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/media?parent=864902"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/categories?post=864902"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/intervacc.se\/en\/wp-json\/wp\/v2\/tags?post=864902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}